Literature DB >> 30690866

Effects of sodium intake on postural lightheadedness: Results from the DASH-sodium trial.

Allison W Peng1, Lawrence J Appel1, Noel T Mueller1, Olive Tang1, Edgar R Miller1, Stephen P Juraschek2.   

Abstract

Lightheadedness after standing contributes to adverse clinical events, including falls. Recommendations for higher sodium intake to treat postural lightheadedness have not been evaluated in a trial setting. The Dietary Approaches to Stop Hypertension (DASH)-Sodium trial (1998-1999) tested the effects of the DASH diet and sodium reduction on blood pressure (BP). Participants were randomly assigned to DASH or a typical Western diet (control). During either diet, participants ate three sodium levels (50, 100, 150 meq/d at 2100 kcal) in random order for 30-days, separated by 5-day breaks. Participants reported the presence and severity of postural lightheadedness at baseline and after each feeding period. There were 412 participants (mean age 48 years; 57% women; 57% black). Mean baseline SBP/DBP was 135/86 mm Hg; 9.5% reported baseline lightheadedness. Among those consuming the DASH diet, high vs low sodium increased lightheadedness (OR 1.71; 95% CI: 1.01, 2.90; P = 0.047) and severity of lightheadedness (P = 0.02), but did not affect lightheadedness in those consuming the control diet (OR 0.77; 95% CI: 0.46, 1.29; P = 0.32). Among those consuming high vs low sodium in the context of the DASH diet, adults <60 vs ≥60 years old experienced more lightheadedness (P-interaction = 0.04), along with obese vs non-obese adults (P-interaction = 0.01). In the context of the DASH diet, higher sodium intake was associated with more frequent and severe lightheadedness. These findings challenge traditional recommendations to increase sodium intake to prevent lightheadedness. ©2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  DASH diet; orthostatic lightheadedness; sodium; trial

Mesh:

Substances:

Year:  2019        PMID: 30690866      PMCID: PMC6420359          DOI: 10.1111/jch.13487

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  47 in total

1.  [Orthostatic hypotension and chronic potassium depletion].

Authors:  R SLAMA; J GUEDON; J P FOUCAULT
Journal:  Coeur Med Interne       Date:  1963-01

2.  Effects of sodium and potassium supplementation on endothelial function: a fully controlled dietary intervention study.

Authors:  Lieke Gijsbers; James I Dower; Casper G Schalkwijk; Yvo H A M Kusters; Stephan J L Bakker; Peter C H Hollman; Johanna M Geleijnse
Journal:  Br J Nutr       Date:  2015-09-07       Impact factor: 3.718

3.  Is potassium a ubiquitous mediator of vasodilation in the central nervous system?

Authors:  Lane K Bekar; Maiken Nedergaard
Journal:  Biophys J       Date:  2013-11-19       Impact factor: 4.033

4.  The role of potassium in postural hypotension: electrolytes and neurohumoral factors in elderly hypertensive patients using diuretics.

Authors:  S Luutonen; P Neuvonen; H Ruskoaho; I Räihä; T Rajala; K Antila; L Sourander
Journal:  J Intern Med       Date:  1995-04       Impact factor: 8.989

5.  Sodium paradoxically reduces the gastropressor response in patients with orthostatic hypotension.

Authors:  Satish R Raj; Italo Biaggioni; Bonnie K Black; Aniket Rali; Jens Jordan; Indu Taneja; Paul A Harris; David Robertson
Journal:  Hypertension       Date:  2006-06-19       Impact factor: 10.190

6.  Orthostatic hypotension in very old individuals living in nursing homes: the PARTAGE study.

Authors:  Filippo Valbusa; Carlos Labat; Paolo Salvi; Maria E Vivian; Olivier Hanon; Athanase Benetos
Journal:  J Hypertens       Date:  2012-01       Impact factor: 4.844

Review 7.  Orthostatic hypotension: framework of the syndrome.

Authors:  Jochanan E Naschitz; Itzhak Rosner
Journal:  Postgrad Med J       Date:  2007-09       Impact factor: 2.401

8.  Effects of sodium salts on plasma renin activity and norepinephrine response to orthostasis in salt-sensitive normotensive subjects.

Authors:  A M Sharma; U Schorr; W Oelkers; A Distler
Journal:  Am J Hypertens       Date:  1993-09       Impact factor: 2.689

9.  Orthostatic Cerebral Hypoperfusion Syndrome.

Authors:  Peter Novak
Journal:  Front Aging Neurosci       Date:  2016-02-16       Impact factor: 5.750

10.  Orthostatic Hypotension and Symptoms in the AASK Trial.

Authors:  Stephen P Juraschek; Edgar R Miller; Lawrence J Appel
Journal:  Am J Hypertens       Date:  2018-05-07       Impact factor: 3.080

View more
  4 in total

1.  Dietary Sodium Intake and Health Indicators: A Systematic Review of Published Literature between January 2015 and December 2019.

Authors:  Katherine J Overwyk; Zerleen S Quader; Joyce Maalouf; Marlana Bates; Jacqui Webster; Mary G George; Robert K Merritt; Mary E Cogswell
Journal:  Adv Nutr       Date:  2020-09-01       Impact factor: 8.701

2.  Effects of sodium intake on postural lightheadedness: Results from the DASH-sodium trial.

Authors:  Allison W Peng; Lawrence J Appel; Noel T Mueller; Olive Tang; Edgar R Miller; Stephen P Juraschek
Journal:  J Clin Hypertens (Greenwich)       Date:  2019-01-28       Impact factor: 3.738

3.  Further evidence that methods based on spot urine samples should not be used to examine sodium-disease relationships from the Science of Salt: A regularly updated systematic review of salt and health outcomes (November 2018 to August 2019).

Authors:  Kristina S Petersen; Daniela Malta; Sarah Rae; Sarah Dash; Jacqui Webster; Rachael McLean; Sudhir Raj Thout; Norm R C Campbell; JoAnne Arcand
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-09-10       Impact factor: 3.738

4.  The Effects of a Low Sodium Meal Plan on Blood Pressure in Older Adults: The SOTRUE Randomized Feasibility Trial.

Authors:  Stephen P Juraschek; Courtney L Millar; Abby Foley; Misha Shtivelman; Alegria Cohen; Virginia McNally; Robert Crevatis; Stephen M Post; Kenneth J Mukamal; Lewis A Lipsitz; Jennifer L Cluett; Roger B Davis; Shivani Sahni
Journal:  Nutrients       Date:  2021-03-16       Impact factor: 5.717

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.